Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11892759 | 1.00 | HPGD (0.45) | HPGDSMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL11892762 | 1.00 | HPGD (0.45) | HPGDSMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL13412867 | 0.94 | HPGD (0.51) | HPGDSMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL11892712 | 0.94 | HPGD (0.51) | HPGDSMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL30110380 | 0.86 | L3MBTL1 (0.51) | KMT2AMEN1POLBMAPT | |
| SCHEMBL10118393 | 0.85 | HPGD (0.45) | HPGDSMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL13674784 | 0.84 | HPGD (0.47) | HPGDSMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL14301360 | 0.84 | HPGD (0.47) | HPGDSMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL13245892 | 0.84 | HPGD (0.47) | HPGDSMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL29191664 | 0.84 | KMT2A (0.51) | HPGDSMN1; SMN2CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283424-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2009116067-A2 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | HPGD 1731/4885SMN1; SMN2 1036/4885CHRM2 3564/4885 |
| US-20170283424-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | HPGD 1731/4885SMN1; SMN2 1036/4885CHRM2 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.